The trial will test four dose levels and include up to 18 patients with advanced, FLT3-expressing acute myeloid leukemia.

The firm aims to use its platform to guide selection of personalized and immunotherapies for cancer patients and to support drug development.

Pfizer opted to discontinue the product for "several reasons," including limited interest from patients and physicians in gene therapies for hemophilia.